Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. - Richardson, Debra L.; Moore, Kathleen N.; Vergote, Ignace; Gilbert, Lucy; Martin, Lainie P.; Mantia-Smaldone, Gina M.; Castro, Cesar M.; Provencher, Diane; Matulonis, Ursula A.; Stec, James; Wang, Yuemei; Method, Michael; et al. (Gynecologic Oncology, 2024)